<DOC>
	<DOCNO>NCT00786123</DOCNO>
	<brief_summary>Irritable bowel syndrome ( IBS ) common chronic gastrointestinal disorder . Existing therapy IBS still far satisfactory new therapy constantly seek . Probiotics promise candidate prevention treatment IBS . However , efficacy mechanism still unclear . The current study aim evaluate effect combination probiotic , VSL # 3 , symptom rectal sensitivity patient IBS . The underlie mechanism also investigate . We recruit forty patient Rome III IBS randomize , parallel group , double-blinded design , take four VSL # 3 capsule placebos , twice daily , six week . Before treatment , patient assess symptom , rectal sensitivity , well saliva fecal melatonin level . Bowel symptom diary weekly satisfactory relief bowel symptom also record evaluate .</brief_summary>
	<brief_title>Exploring Mechanism Probiotic Combination VSL # 3 Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Female male patient IBS age 18 68 recruit . IBS diagnose accord Rome III diagnostic criterion ( Drossman Dumitrascu , 2006 ) . The history previous chronic GI symptom suggestive IBS least 3 month ( necessarily consecutive ) precede 6 month . The stool culture subject negative hemoccult , pathogen ( Salmonella Shigella ) , parasites ( Giardia ) ova/ cyst . Only patient IBS symptoms least one month prior study whose IBS symptom score least moderate severity least one IBS symptom eligible inclusion study . Those subject unwilling unable give inform consent , follow protocol stop medication use treat diarrhoea colitis Subject take time propose enrolment list prohibited medication : Anticholinergics ( dicyclomine , hyoscyamine , propantheline ) Cholinomimetic agent ( bethanechol etc . ) All narcotic ( morphine , codeine , propoxyphene either alone combination ) 5HT3 receptor antagonist ( e.g. , alosetron , ondansetron , tropisetron , dolasetron , granisetron ) . Gastrointestinal preparation : Antacids ( contain either magnesium aluminium ) Antidiarrheal agent Bismuth compound Laxatives ( stimulant osmotic ) Sulfasalazine Treatment immunosuppressive medication presence immunocompromised state If currently use medication ( like use Diabetes mellitus , Sarcoidosis , Connective tissue disease , poorly control hypo/hyperthyroidism ) may alter bowel motility long term antibiotic therapy Use investigational drug and/or participation clinical trial within 3 month entry study Patients exclude undergone previous abdominal surgery ( except appendectomy , Caesarean section , Cholecystectomy , Tubal ligation , Hysterectomy , Hernia repair â‰¥ 6 month prior enrolment ) Subject diagnose follow GI disorder : Inflammatory bowel disease ( Crohn 's disease , Ulcerative colitis , Indeterminate Colitis Microscopic colitis ( lymphocytic colitis , collagenous colitis ) Celiac Disease Gastroparesis Gastrointestinal obstruction and/or stricture Chronic pancreatitis Subject significant concomitant psychiatric , neurological , metabolic , renal , hepatic , infection , hematological , C.V pulmonary illness , unless condition stable judged investigator condition interfere patient participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>rectal hypersensitivity</keyword>
	<keyword>probiotic</keyword>
	<keyword>melatonin</keyword>
	<keyword>brain-gut axis</keyword>
</DOC>